Peptide oligonucleotide conjugates
Oligonucleotide analogues conjugated to carrier peptides are provided. The disclosed compounds are useful for the treatment of various diseases, for example diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.
1. A conjugate comprising:
(a) a carrier peptide comprising amino acid subunits, the carrier peptide comprising a glycine (G) or proline (P) amino acid subunit at the carboxy terminus of the carrier peptide;
(b) a phosphorodiamidate morpholino oligomer (PMO) comprising a substantially uncharged backbone and a targeting base sequence for sequence-specific binding to a target nucleic acid; and
(c) a covalent attachment between the morpholino oligomer and the carrier peptide, the covalent attachment consisting of an amide bond to the carboxy-terminal glycine or proline and an optional linker group;
wherein:
two or more of the amino acid subunits are positively charged amino acids, no more than seven contiguous amino acid subunits are arginine.
2. The conjugate of claim 1 , wherein the carrier peptide comprises a glycine amino acid at the carboxy terminus.
3. The conjugate of claim 1 , wherein the carrier peptide comprises a proline amino acid at the carboxy terminus.
4. The conjugate of claim 1 , wherein the carrier peptide comprises from 4 to 40 amino acid subunits.
5. The conjugate of claim 1 , wherein the carrier peptide comprises from 6 to 20 amino acid subunits.
6. The conjugate of claim 1 , wherein the positively charged amino acids are histidine (H), lysine (K), arginine (R) or combinations thereof.
7. The conjugate of claim 1 , wherein at least one of the positively charged amino acids is arginine.
8. The conjugate of claim 1 , wherein each of the positively charged amino acids is arginine.
9. The conjugate of claim 1 , wherein at least one of the positively charged amino acids is an arginine analog, the arginine analog being a cationic α-amino acid comprising a side chain of the structure R a N═C(NH 2 )R b , where R a is H or R c ; R b is R c , NH 2 , NHR, or N(R c ) 2 , where R c is lower alkyl or lower alkenyl and optionally comprises oxygen or nitrogen or R a and R b may together form a ring; and wherein the side chain is linked to the amino acid via R a or R b .
10. The conjugate of claim 1 , wherein at least 20% of the amino acid subunits are positively charged amino acids.
11. The conjugate of claim 1 , wherein at least 50% of the amino acid subunits are positively charged amino acids.
12. The conjugate of claim 1 , wherein at least 80% of the amino acid subunits are positively charged amino acids.
13. The conjugate of claim 1 , wherein all of the amino acid subunits, except the carboxy terminal glycine or proline, are positively charged amino acids.
14. The conjugate of claim 1 , wherein the carrier peptide comprises the sequence (R d ) m , wherein R d is independently, at each occurrence, a positively charged amino acid and m is an integer ranging from 2 to 12.
15. The conjugate of claim 14 , wherein R d is independently, at each occurrence, arginine, hystidine or lysine.
16. The conjugate of claim 14 , wherein each R d is arginine.
17. The conjugate of claim 1 , wherein each amino acid subunit, except the carboxy terminal glycine or proline, is arginine.
18. The conjugate of claim 1 , wherein the carrier peptide comprises at least one hydrophobic amino acid, the hydrophobic amino acid comprising a substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl or aralkyl side chain wherein the alkyl, alkenyl and alkynyl side chain includes at most one heteroatom for every six carbon atoms.
19. The conjugate of claim 18 , wherein the carrier peptide comprises two or more hydrophobic amino acids.